Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:clinicalTrialStartDate |
December 2020
|
| gptkbp:countryOfOrigin |
gptkb:Germany
|
| gptkbp:developedBy |
gptkb:CureVac
|
| gptkbp:discontinued |
October 2021
lower efficacy compared to other vaccines |
| gptkbp:doseInterval |
28 days
|
| gptkbp:EMAStatus |
not approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
CVnCoV
|
| gptkbp:numberOfDoses |
2
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:status |
development discontinued
|
| gptkbp:storage |
2–8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:technology |
synthetic mRNA encoding SARS-CoV-2 spike protein
|
| gptkbp:vaccineType |
vaccine
|
| gptkbp:WHOStatus |
not approved
|
| gptkbp:bfsParent |
gptkb:CureVac
|
| gptkbp:bfsLayer |
7
|